



*Imaging biomarkers are key to detecting and treating cancer*

Press Release

## **MEDIAN Technologies Awarded Phase II Oncology Trial in Asia**

*MEDIAN Technologies selected by Oxford Oncology  
to provide imaging solutions and services  
in a phase II clinical trial on lung cancer*

**Sophia Antipolis, France – April, 17 2013** – MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced today it has been selected as the imaging solutions and services provider in a new phase II clinical trial on Non Small Cell Lung Cancer (NSCLC). The trial is sponsored by Oxford Oncology, a global biopharmaceutical company developing anti-cancer therapies and will include clinical sites located in four Asian countries: Japan, China, Korea and Taiwan.

*“This project provides further proof of our growing operational strengths in Asia and our commitment to support our customers in this important region,”* said Fredrik Brag, CEO of MEDIAN Technologies. *“We now have a number of ongoing studies in various countries in Asia, and we have a growing installed base of imaging centers using our Lesion Management Solutions (LMS) software for these trials. This is an exciting study and we look forward to developing a long-term partnership with Oxford Oncology.”* Fredrik Brag added.

MEDIAN will organize the independent central reviews of the images for this study. MEDIAN services will notably include charter drafting, investigator site support, image collection and quality control, image review by radiologists with MEDIAN LMS, a comprehensive suite of software modules for the review of images and quantitative assessment of response to therapy in clinical trials.

Images will be acquired in 50 Asia-based clinical sites, with an anticipated total enrollment of 250 patients.

The total project award is approximately €417,000 (eq. \$545,500) for MEDIAN.



# MEDIAN

*Imaging biomarkers are key to detecting and treating cancer*

**ALMDT**  
**LISTED**  
**NYSE**  
**ALTERNEXT**

**About MEDIAN Technologies:** MEDIAN Technologies provides advanced imaging solutions for diagnosing and monitoring cancer patients in clinical trials and in routine clinical practice. MEDIAN collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), the University of Chicago, and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN is present in the market through direct and indirect sales of its LMS solutions and through alliances with specialist cancer centers in Europe and the USA.

MEDIAN has a strategic partnership with Canon for the development of new technologies, and a strategic partnership with Quintiles to offer integrated imaging services for clinical trials to customers worldwide.

Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag (CEO), Gérard Milhiet, and Arnaud Butzbach. The company has a staff of 45, over half of whom work in R&D, and has a US-based subsidiary in the Boston area.

MEDIAN has received the label "Innovative company" by OSEO and is listed on NYSE Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT).

For more information on MEDIAN, please visit: [www.mediantechologies.com](http://www.mediantechologies.com)

## CONTACTS

### **MEDIAN Technologies**

Fredrik Brag, CEO  
+33 492 906 582  
[fredrik.brag@mediantechnologies.com](mailto:fredrik.brag@mediantechnologies.com)

### **Press**

**ALIZE RP**  
Caroline Carmagnol  
+ 33 664 189 959  
+ 33 142 688 643  
[caroline@alizerp.com](mailto:caroline@alizerp.com)

### **Investors**

**ACTIFIN**  
Anaïs de Scitivaux  
+ 33 156 881 114  
[adescitivaux@actifin.fr](mailto:adescitivaux@actifin.fr)

Christian Berg  
+ 33 142 688 641  
[christian@alizerp.com](mailto:christian@alizerp.com)